Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
Dyne Therapeutics Inc (NASDAQ: DYN) closed the day trading at $11.89 down -3.49% from the previous closing price of $12.32. In other words, the price has decreased by -$3.49 from its previous closing price. On the day, 3.03 million shares were traded.
Ratios:
For a better understanding of DYN, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 15.60 and its Current Ratio is at 15.60. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.03.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Robert W. Baird on December 13, 2024, initiated with a Outperform rating and assigned the stock a target price of $46.
On November 26, 2024, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $45.
JP Morgan Downgraded its Overweight to Neutral on October 24, 2024, whereas the target price for the stock was revised from $43 to $35.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 18 ’25 when Beskrovnaya Oxana sold 2,598 shares for $13.95 per share. The transaction valued at 36,242 led to the insider holds 199,087 shares of the business.
Scalzo Richard William sold 2,488 shares of DYN for $34,708 on Feb 18 ’25. The SVP, Head of Finance & Admin. now owns 124,590 shares after completing the transaction at $13.95 per share. On Feb 18 ’25, another insider, Scalzo Richard William, who serves as the Officer of the company, bought 2,488 shares for $13.91 each.
Stock Price History:
Over the past 52 weeks, DYN has reached a high of $47.45, while it has fallen to a 52-week low of $12.28. The 50-Day Moving Average of the stock is -29.84%, while the 200-Day Moving Average is calculated to be -60.83%.
Shares Statistics:
A total of 102.32M shares are outstanding, with a floating share count of 75.60M. Insiders hold about 25.71% of the company’s shares, while institutions hold 90.09% stake in the company.
Earnings Estimates
The market rating of Dyne Therapeutics Inc (DYN) is currently shaped by the ongoing analysis conducted by 8.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.87, with high estimates of -$0.67 and low estimates of -$1.06.
Analysts are recommending an EPS of between -$2.78 and -$4.37 for the fiscal current year, implying an average EPS of -$3.52. EPS for the following year is -$3.75, with 8.0 analysts recommending between -$3.1 and -$4.85.
